Previous close | 5.40 |
Open | N/A |
Bid | 6.20 |
Ask | 9.30 |
Strike | 45.00 |
Expiry date | 2024-12-20 |
Day's range | 5.40 - 5.40 |
Contract range | N/A |
Volume | |
Open interest | 4 |
ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3 Sarclisa, in combination with standard-of-care bortezomib, lenalidomide and dexamethasone (VRd) followed by Sarclisa-Rd reduced the risk of recurrence or death by 40% versus VRd followed by Rd in the investigational use for transplant-ineligible newly diagnosed multiple myeloma patientsKey primary endpoint of progressio
On Monday, GSK Plc (NYSE:GSK) shares were down after the Delaware State Court ruled that more than 70,000 lawsuits could proceed over its discontinued heartburn drug, Zantac (ranitidine). The State Court’s decision contradicts the Federal Court’s Multidistrict Litigation ruling under the same legal standard, which dismissed all cases alleging five cancer types in December 2022. GSK says the litigation in Delaware remains at an early stage, and the ruling, under the Daubert standard, relates only
On Friday, the FDA extended the target action date of priority review of supplemental application seeking approval for Dupixent (dupilumab) as an add-on maintenance treatment in certain adult patients with uncontrolled chronic obstructive pulmonary disease (COPD), a lung disease that’s usually caused by smoking. The revised target action date is September 27, 2024. The FDA accepted the application in February, with a target action date of June 27, 2024. The FDA did not raise any concerns regardi